SCHEMBL4346296

SCHEMBL4346296

CN(CCO[Si](C)(C)C(C)(C)C)c1ccc(C(=O)O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
NTSR1 P30989 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
HCAR3 P49019 1/20 0.37
HPGD P15428 1/20 0.37
DGAT1 O75907 3/20 0.36
DUT P33316 2/20 0.36
PLA2G2A P14555 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SRD5A2 P31213 1/20 0.34
KDM4A O75164 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
NR4A2 P43354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1756645 0.84 CA12 (0.43) MEN1NPC1POLBKMT2AHPGD
SCHEMBL5854799 0.80 DUT (0.39) NTSR1HPGDDGAT1DUT
SCHEMBL12422405 0.79 CYP2A6 (0.42) NTSR1MEN1KMT2AHPGDDGAT1
SCHEMBL10210038 0.79 NTSR1 (0.33) NTSR1MEN1KMT2ADGAT1
SCHEMBL12422407 0.78 KDM4E (0.38) NTSR1HPGDDUTL3MBTL1
SCHEMBL1756743 0.77 MEN1 (0.45) MEN1NPC1POLBKMT2AHCAR3
SCHEMBL4741957 0.77 ALDH1A1 (0.44) MEN1KMT2AHPGDRXRARXRB
SCHEMBL98971 0.76 DUT (0.34) NTSR1KMT2ADGAT1DUT
SCHEMBL14966079 0.75 POLB (0.35) POLBRXRARXRBRXRGNR4A2
SCHEMBL16863153 0.74 HDAC1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258893-A1 FUSED QUINOLINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-15 US disclosed
US-7592453-B2 Fused quinoline derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-22 US disclosed
US-20080039452-A1 Fused Quinoline Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258893-A1 FUSED QUINOLINE DERIVATIVE AND USE THEREOF TACR2, HRH3, HRH2 NR1H2 275/4885NR1H3 445/4885NTSR1 35/4885
US-20080039452-A1 Fused Quinoline Derivative and Use Thereof TACR2, HRH3, HRH2 NR1H2 271/4885NR1H3 441/4885NTSR1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.